{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T02:46:43Z","timestamp":1789958803346,"version":"4.0.1"},"reference-count":33,"publisher":"American Society of Hematology","issue":"2","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2013,1,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Molecular response to imatinib (IM) in chronic myeloid leukemia (CML) is associated with a biphasic but heterogeneous decline of BCR-ABL transcript levels. We analyzed this interindividual heterogeneity and provide a predictive mathematical model to prognosticate the long-term response and the individual risk of molecular relapse on treatment cessation. The parameters of the model were determined using 7-year follow-up data from a randomized clinical trial and validated by an independent dataset. Our model predicts that a subset of patients (14%) achieve complete leukemia eradication within less than 15 years and could therefore benefit from discontinuation of treatment. Furthermore, the model prognosticates that 31% of the patients will remain in deep molecular remission (MR5.0) after treatment cessation after a fixed period of 2 years in MR5.0, whereas 69% are expected to relapse. As a major result, we propose a predictor that allows to assess the patient-specific risk of molecular relapse on treatment discontinuation and to identify patients for whom cessation of therapy would be an appropriate option. Application of the suggested rule for deciding about the time point of treatment cessation is predicted to result in a significant reduction in rate of molecular relapse.<\/jats:p>","DOI":"10.1182\/blood-2012-07-441956","type":"journal-article","created":{"date-parts":[[2012,11,23]],"date-time":"2012-11-23T01:34:02Z","timestamp":1353634442000},"page":"378-384","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":66,"title":["Model-based decision rules reduce the risk of molecular relapse after cessation of tyrosine kinase inhibitor therapy in chronic myeloid leukemia"],"prefix":"10.1182","volume":"121","author":[{"given":"Matthias","family":"Horn","sequence":"first","affiliation":[{"name":"Institute for Medical Informatics, Statistics and Epidemiology, University of Leipzig, Leipzig, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ingmar","family":"Glauche","sequence":"additional","affiliation":[{"name":"Institute for Medical Informatics and Biometry, Faculty of Medicine Carl Gustav Carus, Dresden University of Technology, Dresden, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin C.","family":"M\u00fcller","sequence":"additional","affiliation":[{"name":"III Medizinische Klinik, Medizinische Fakult\u00e4t Mannheim, University of Heidelberg, Mannheim, Germany; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R\u00fcdiger","family":"Hehlmann","sequence":"additional","affiliation":[{"name":"III Medizinische Klinik, Medizinische Fakult\u00e4t Mannheim, University of Heidelberg, Mannheim, Germany; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Hochhaus","sequence":"additional","affiliation":[{"name":"Abt H\u00e4matologie\/Onkologie, Universit\u00e4tsklinikum Jena, Jena, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"Loeffler","sequence":"additional","affiliation":[{"name":"Institute for Medical Informatics, Statistics and Epidemiology, University of Leipzig, Leipzig, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ingo","family":"Roeder","sequence":"additional","affiliation":[{"name":"Institute for Medical Informatics and Biometry, Faculty of Medicine Carl Gustav Carus, Dresden University of Technology, Dresden, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"9584","key":"2019111808492367600_B1","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1016\/S0140-6736(07)61165-9","article-title":"Chronic myeloid leukaemia.","volume":"370","author":"Hehlmann","year":"2007","journal-title":"Lancet"},{"issue":"6","key":"2019111808492367600_B2","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1038\/nrc2147","article-title":"Chronic myeloid leukaemia as a model of disease evolution in human cancer.","volume":"7","author":"Melo","year":"2007","journal-title":"Nat Rev Cancer"},{"issue":"9","key":"2019111808492367600_B3","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1056\/NEJMra013339","article-title":"Imatinib mesylate: a new oral targeted therapy.","volume":"346","author":"Savage","year":"2002","journal-title":"N Engl J Med"},{"issue":"24","key":"2019111808492367600_B4","doi-asserted-by":"crossref","first-page":"2260","DOI":"10.1056\/NEJMoa1002315","article-title":"Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia.","volume":"362","author":"Kantarjian","year":"2010","journal-title":"N Engl J Med"},{"issue":"24","key":"2019111808492367600_B5","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1056\/NEJMoa0912614","article-title":"Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia.","volume":"362","author":"Saglio","year":"2010","journal-title":"N Engl J Med"},{"issue":"1","key":"2019111808492367600_B6","first-page":"100","article-title":"Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative.","volume":"56","author":"Buchdunger","year":"1996","journal-title":"Cancer Res"},{"issue":"5","key":"2019111808492367600_B7","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1038\/nm0596-561","article-title":"Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells.","volume":"2","author":"Druker","year":"1996","journal-title":"Nat Med"},{"issue":"5","key":"2019111808492367600_B8","first-page":"1958","article-title":"The tyrosine kinase inhibitor CGP 57148 (STI 571) induces apoptosis in BCR-ABL-positive cells by down-regulating BCL-X.","volume":"6","author":"Oetzel","year":"2000","journal-title":"Clin Cancer Res"},{"issue":"2","key":"2019111808492367600_B9","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1038\/84683","article-title":"Induction of apoptosis in chronic myelogenous leukaemia cells through nuclear entrapment of BCR-ABL tyrosine kinase.","volume":"7","author":"Vigneri","year":"2001","journal-title":"Nat Med"},{"issue":"7046","key":"2019111808492367600_B10","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1038\/nature03669","article-title":"Dynamics of chronic myeloid leukemia.","volume":"435","author":"Michor","year":"2005","journal-title":"Nature"},{"issue":"10","key":"2019111808492367600_B11","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1038\/nm1487","article-title":"Dynamic modeling of imatinib-treated chronic myeloid leukemia: functional insights and clinical implications.","volume":"12","author":"Roeder","year":"2006","journal-title":"Nat Med"},{"issue":"6","key":"2019111808492367600_B12","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1016\/j.cell.2008.10.048","article-title":"Hematopoietic stem cells reversibly switch from dormancy to self-renewal during homeostasis and repair.","volume":"135","author":"Wilson","year":"2008","journal-title":"Cell"},{"issue":"7","key":"2019111808492367600_B13","doi-asserted-by":"crossref","first-page":"e1000447","DOI":"10.1371\/journal.pcbi.1000447","article-title":"Stem cell proliferation and quiescence: two sides of the same coin.","volume":"5","author":"Glauche","year":"2009","journal-title":"PLoS Comput Biol"},{"issue":"6","key":"2019111808492367600_B14","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1038\/leu.2009.38","article-title":"Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia.","volume":"23","author":"Hochhaus","year":"2009","journal-title":"Leukemia"},{"issue":"1","key":"2019111808492367600_B15","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1053\/beha.2001.0190","article-title":"Minimal residual disease in chronic myeloid leukaemia patients.","volume":"15","author":"Hochhaus","year":"2002","journal-title":"Best Pract Res Clin Haematol"},{"issue":"1","key":"2019111808492367600_B16","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1097\/01.moh.0000148551.93303.9e","article-title":"Monitoring minimal residual disease in BCR-ABL-positive chronic myeloid leukemia in the imatinib era.","volume":"12","author":"Goldman","year":"2005","journal-title":"Curr Opin Hematol"},{"issue":"10","key":"2019111808492367600_B17","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1038\/leu.2010.185","article-title":"Patients with chronic myeloid leukemia who maintain a complete molecular response after stopping imatinib treatment have evidence of persistent leukemia by DNA PCR.","volume":"24","author":"Ross","year":"2010","journal-title":"Leukemia"},{"issue":"11","key":"2019111808492367600_B18","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1016\/S1470-2045(10)70233-3","article-title":"Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial.","volume":"11","author":"Mahon","year":"2010","journal-title":"Lancet Oncol"},{"issue":"8","key":"2019111808492367600_B19","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1016\/S0301-472X(02)00832-9","article-title":"A novel dynamic model of hematopoietic stem cell organization based on the concept of within-tissue plasticity.","volume":"30","author":"Roeder","year":"2002","journal-title":"Exp Hematol"},{"issue":"1-2","key":"2019111808492367600_B20","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1159\/000118786","article-title":"Mathematical modeling of genesis and treatment of chronic myeloid leukemia.","volume":"188","author":"Horn","year":"2008","journal-title":"Cells Tissues Organs"},{"issue":"12","key":"2019111808492367600_B21","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1200\/JCO.2010.32.0598","article-title":"Tolerability-adapted imatinib 800 mg\/d versus 400 mg\/d versus 400 mg\/d plus interferon-\u03b1 in newly diagnosed chronic myeloid leukemia.","volume":"29","author":"Hehlmann","year":"2011","journal-title":"J Clin Oncol"},{"issue":"1","key":"2019111808492367600_B22","first-page":"33","article-title":"Hypothesis testing when a nuisance parameter is present only under the alternative.","volume":"74","author":"Davies","year":"1987","journal-title":"Biometrika"},{"issue":"10","key":"2019111808492367600_B23","doi-asserted-by":"crossref","first-page":"2172","DOI":"10.1038\/leu.2012.104","article-title":"Standardized definitions of molecular response in chronic myeloid leukemia.","volume":"26","author":"Cross","year":"2012","journal-title":"Leukemia"},{"issue":"11","key":"2019111808492367600_B24","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1038\/leu.2010.159","article-title":"Insights into the stem cells of chronic myeloid leukemia.","volume":"24","author":"Sloma","year":"2010","journal-title":"Leukemia"},{"issue":"1","key":"2019111808492367600_B25","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1182\/blood.V99.1.319","article-title":"Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro.","volume":"99","author":"Graham","year":"2002","journal-title":"Blood"},{"issue":"5","key":"2019111808492367600_B26","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/j.molonc.2010.06.001","article-title":"Targeting leukemic stem cells by breaking their dormancy.","volume":"4","author":"Essers","year":"2010","journal-title":"Mol Oncol"},{"issue":"6","key":"2019111808492367600_B27","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.1182\/blood-2011-02-339267","article-title":"Dynamics of chronic myeloid leukemia response to long-term targeted therapy reveal treatment effects on leukemic stem cells.","volume":"118","author":"Tang","year":"2011","journal-title":"Blood"},{"issue":"21","key":"2019111808492367600_B28","doi-asserted-by":"crossref","first-page":"6812","DOI":"10.1158\/1078-0432.CCR-11-0396","article-title":"BCR-ABL transcript dynamics support the hypothesis that leukemic stem cells are reduced during imatinib treatment.","volume":"17","author":"Stein","year":"2011","journal-title":"Clin Cancer Res"},{"key":"2019111808492367600_B29","doi-asserted-by":"crossref","first-page":"S39","DOI":"10.1016\/j.leukres.2003.10.007","article-title":"Molecular mechanisms of resistance of leukemia to imatinib mesylate.","volume":"28","author":"Tauchi","year":"2004","journal-title":"Leuk Res"},{"issue":"8","key":"2019111808492367600_B30","doi-asserted-by":"crossref","first-page":"3118","DOI":"10.1182\/blood.V86.8.3118.3118","article-title":"Detection of major BCR-ABL gene expression at a very low level in blood cells of some healthy individuals.","volume":"86","author":"Biernaux","year":"1995","journal-title":"Blood"},{"issue":"9","key":"2019111808492367600_B31","doi-asserted-by":"crossref","first-page":"e1000503","DOI":"10.1371\/journal.pcbi.1000503","article-title":"Eradication of chronic myeloid leukemia stem cells: a novel mathematical model predicts no therapeutic benefit of adding G-CSF to imatinib.","volume":"5","author":"Foo","year":"2009","journal-title":"PLoS Comput Biol"},{"issue":"10","key":"2019111808492367600_B32","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.3324\/haematol.2012.062844","article-title":"Selection pressure exerted by imatinib therapy leads to disparate outcomes of imatinib discontinuation trials.","volume":"97","author":"Tang","year":"2012","journal-title":"Haematologica"},{"issue":"24","key":"2019111808492367600_B33","doi-asserted-by":"crossref","first-page":"2314","DOI":"10.1056\/NEJMe1004430","article-title":"Even better kinase inhibitors for chronic myeloid leukemia.","volume":"362","author":"Sawyers","year":"2010","journal-title":"N Engl J Med"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/121\/2\/378\/1364386\/zh800213000378.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/121\/2\/378\/1364386\/zh800213000378.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,18]],"date-time":"2019-11-18T14:53:02Z","timestamp":1574088782000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/121\/2\/378\/30970\/Modelbased-decision-rules-reduce-the-risk-of"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,1,10]]},"references-count":33,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2013,1,10]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2012-07-441956","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,1,10]]}}}